miRagen Therapeutics Reaches Funding Milestones, Secures Series A Extension

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing microRNA (miRNA) based therapeutics for cardiovascular and muscle disease, announced the achievement of several key milestones resulting in the approval of the second tranche of last year's $8 million Series A financing.

In addition, miRagen secured a $4 million extension of the Series A, bringing the total funding of the Series A financing to $12 million, the company noted in a release. New investors Amgen Ventures, Broadview Ventures and The Peierls Foundation join founding investors Atlas Venture and Boulder Ventures, in funding the company's novel development of microRNA modulators as therapeutic agents for cardiovascular and muscle disorders.

"Our team has been able to execute on several vital goals. Achieving these milestones and securing this financing have better positioned us to capitalize on our research and development pipeline," said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen Therapeutics, Inc. "We welcome the addition of our new investors and appreciate the continued commitment from our current investors."

"miRagen has delivered compelling in vivo efficacy results from systemic administration of our proprietary anti-miR candidates," added Bruce Booth, D.Phil., Chairman of miRagen's Board of Directors and Partner, Atlas Venture. "The company's progress to date has been very impressive, and the additional financing will help to facilitate the next stage of development of this exciting new class of drug candidates."

((Comments on this story may be sent to health@closeupmedia.com))

Related terms: cardiovascular, ceo, disease, foundation, health, pipeline, president, research and development